2017 Press Releases

Portfolio Companies

Aptinyx logo

Save

Save

Save

Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders (PDF Download)
December 18, 2017

Principia

Principia Biopharma initiates clinical trial for PRN1008 in patients with Immune Thrombocytopenia Purpura December 13, 2017

Aptinyx logo

Save

Save

Save

Aptinyx Granted Fast Track Designation, Initiates Phase 1 for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder (PDF Download)
December 7, 2017

Aptinyx logo

Save

Save

Save

Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer (PDF Download)
December 7, 2017

Crispr logo

Save

Save

CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia
December 7, 2017

Arvinas and Macroceutics Establish DEL Screening Collaboration on Undruggable Targets
November 21, 2017

Kyruus logo

Save

Jefferson Health Selects Kyruus’ Solutions to Support Its Expansion and Enhance Patient Access
November 15, 2017

Arvinas Expands Strategic License Agreement with Genentech
November 15, 2017

Principia

Sanofi, Principia Agree To Develop Multiple Sclerosis Drug Candidate
November 9, 2017

Harpoon Therapeutics logo

Save

AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration
October 18, 2017

Neuronetics Logo

Save

Save

Neuronetics, Inc. Partners with Teijin Pharma Limited, a Leading Healthcare Company in Japan, to Distribute NeuroStar Advanced Therapy
October 16, 2017

Neuronetics Logo

Save

Save

NeuroStar® Advanced Therapy Approved as a Life-Changing Depression Treatment to Help Conquer Depression in Japan
October 11, 2017

Neuronetics Named 2017 Health Care Innovator by Philadelphia Business Journal
Recognized for company’s breakthrough non-drug depression treatment, NeuroStar® Advanced Therapy
October 9, 2017

Dimension logo

Save

Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares
October 3, 2017

Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering
September 27, 2017

Kyruus logo

Save

Kyruus ProviderMatch™ to Help Emory Healthcare Raise the Bar on Patient Access
September 26, 2017

Karus

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial
September 18, 2017

Truveris logo

Save

Alysha Fluno Joins Truveris as Chief Pharmacy Officer
September 15, 2017

Deciphera logo

Save

Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma
September 5, 2017

Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma
August 23, 2017

CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies
August 22, 2017

Binary Fountain and Kyruus Announce Partnership to Enhance Patient Acquisition and Engagement for Health Systems
August 15, 2017

Oxford Immunotec Logo

Save

Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares
August 15, 2017

Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions
August 1, 2017

Save

Iterum Gains Important Support for Development of Noval Oral Atibiotic, Sulopenem
July 25, 2017

Kyruus logo

Save

Baylor Scott & White Health Selects Kyruus’ Solutions to Enhance Provider Data Management and Patient Access
July 13, 2017

NJEA: Union-led Effort Nets $1.6 Billion in Prescription Savings
July 5, 2017

Oxford Immunotec Announces National Reimbursement for the T-SPOT TB Test in France
June 22, 2017

Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
June 15, 2017

Kyruus Enhances Its Clinical Leadership with New Chief Medical Officer, Erin Jospe, M.D.
June 13, 2017

AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors
June 13, 2017

Neuronetics, Inc. Raises $15 Million in Series G Equity Financing
June 6, 2017

Deciphera Pharmaceuticals Announces $52 Million Series C Financing to Advance Novel Clinical Stage Oncology Pipeline
June 1, 2017

Harpoon Therapeutics Announces Completion Of $45M Series B Financing
May 25, 2017

Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics
May 23, 2017

Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology
May 22, 2017

Iterum Secures $65 Million in Series B Financing
May 19, 2017

Truveris selected by New Jersey to implement reverse auction and price transparency platform for pharmaceutical benefits
April, 28, 2017

Banner Health Selects Kyruus for Its Patient Access and Provider Data Management Solutions
April 11, 2017

Deciphera Pharmaceuticals Initiates a Phase 1 Clinical Trial of DCC-3014
March 6, 2017

Mercy Health and Kyruus Forge Strategic Partnership to Further Enterprise-Wide Patient Access
February 17, 2017

Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium
February 17, 2017

TigerText Launches Role-based Scheduling Automation
February 16, 2017

Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes
February 3, 2017

Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
January 31, 2017

Intarcia and Calibr Announce Collaboration and In-Licensing Deal Aimed at Delivering a Next Generation Combination Product for Diabetes and Obesity
January 9, 2017

Arvinas logo

Save

Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer
January 5, 2017

Kyruus logo

Save

Piedmont Healthcare Selects Kyruus’ Suite of Patient-Provider Matching Solutions
January 4, 2017